Literature DB >> 8544839

The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription.

T Jin1, D J Drucker.   

Abstract

The gene encoding proglucagon is restricted in expression to the central nervous system, endocrine pancreas, and intestine. Transgenic experiments indicate that the proglucagon gene upstream enhancer (GUE) element is a principal determinant of both the tissue specificity and the relative level of proglucagon gene transcription. We have now sequenced the rat proglucagon GUE and analyzed the transcriptional properties of proglucagon-luciferase fusion genes (that contain 5'- and 3'-deletions in the GUE) after transfection of islet (InR1-G9) and enteroendocrine (STC-1 and GLUTag) cell lines. The GUE contains both positive and negative elements that are recognized differentially in islet vs. intestinal cell lines. The transcriptional properties of the GUE sequences were more similar in cell lines of intestinal (STC-1 and GLUTag) compared with islet (InR1-G9) phenotypes. The electrophoretic mobility shift assay was used to identify specific domains of the GUE that interacted with nuclear proteins from islet and intestinal cells. Several GUE sequences recognized proteins present in both fibroblast and endocrine cell lines. In contrast, electrophoretic mobility shift assay experiments also identified 1) GUE-protein complexes common to both islet and intestinal cell lines and 2) GUE-protein complexes specific to either islet or intestinal lineages. One of the GUE subdomains, designated GLUE1, displayed enhancer-like activity in InR1-G9 and GLUTag, but not BHK, cell lines. Taken together, these observations demonstrate that the proglucagon GUE is comprised of multiple positive and negative domains that likely function in a combinatorial fashion to regulate islet and intestinal-specific proglucagon gene transcription.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8544839     DOI: 10.1210/mend.9.10.8544839

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  7 in total

1.  Ectopic expression of glucagon receptor in skeletal muscles improves glucose homeostasis in a mouse model of diabetes.

Authors:  A Maharaj; L Zhu; F Huang; H Qiu; H Li; C Y Zhang; T Jin; Q Wang
Journal:  Diabetologia       Date:  2012-02-09       Impact factor: 10.122

2.  Intestinal mTOR regulates GLP-1 production in mouse L cells.

Authors:  Geyang Xu; Ziru Li; Li Ding; Hong Tang; Song Guo; Hongbin Liang; Huadong Wang; Weizhen Zhang
Journal:  Diabetologia       Date:  2015-06-03       Impact factor: 10.122

3.  Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Diet-Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21.

Authors:  Lili Tian; Hongmei Ning; Weijuan Shao; Zhuolun Song; Yasaman Badakhshi; Wenhua Ling; Burton B Yang; Patricia L Brubaker; Tianru Jin
Journal:  J Nutr       Date:  2020-08-01       Impact factor: 4.798

Review 4.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

5.  Protein hydrolysates stimulate proglucagon gene transcription in intestinal endocrine cells via two elements related to cyclic AMP response element.

Authors:  J-C Gevrey; M Malapel; J Philippe; G Mithieux; J-A Chayvialle; J Abello; M Cordier-Bussat
Journal:  Diabetologia       Date:  2004-04-14       Impact factor: 10.122

6.  Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment.

Authors:  Mina Rasouli; Zalinah Ahmad; Abdul Rahman Omar; Zeenathul N Allaudin
Journal:  BMC Biotechnol       Date:  2011-11-03       Impact factor: 2.563

7.  SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice.

Authors:  Yanling Zhang; Kerri Thai; Tianru Jin; Minna Woo; Richard E Gilbert
Journal:  Sci Rep       Date:  2018-09-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.